Das Anthony V, Narayanan Raja, Rani Padmaja K
Department of eyeSmart Electronic Medical Record (EMR) and AEye, L. V. Prasad Eye Institute, Hyderabad, IND.
Department of Vitreoretinal Diseases, L. V. Prasad Eye Institute, Hyderabad, IND.
Cureus. 2021 Oct 30;13(10):e19148. doi: 10.7759/cureus.19148. eCollection 2021 Oct.
This study aimed to describe the demographics and clinical profile of patients with diabetic retinopathy (DR) presenting during the novel coronavirus disease 2019 (COVID-19) lockdown and unlock phases in India.
This hospital-based cross-sectional study included patients presenting from March 25, 2019, to March 31, 2021. All patients who presented with DR were included as cases. The data were collected using an electronic medical record system.
In total, 88,012 patients diagnosed with retinal diseases were presented to the network and included for analysis. There were 21,271 (24%) DR patients during the study period and the majority were men (71%) from the urban area (45%). An increasing number of patients with proliferative DR (56%), sight-threatening DR (79%), need for vitreoretinal procedures (31%), and intravitreal injections (19%) were seen during the lockdown (phase one-four). There was a significant increase in the number of patients with blindness in pre-lockdown (20%), lockdown (32%), and post-lockdown (26%). Patterns of sight-threatening DR and blindness were similar in both fresh and follow-up patients.
The presentation of DR patients in hospital is evolving because of the COVID-19 pandemic. The footfalls of patients during the unlock (phase 1-10) regained to two-thirds of the pre-COVID-19 level. There was an increase in patients with sight-threatening DR and the need for vitreoretinal surgery and intravitreal injections during the lockdown (phase 1-4).
本研究旨在描述在印度2019年新型冠状病毒病(COVID-19)封锁和解封阶段出现的糖尿病视网膜病变(DR)患者的人口统计学和临床特征。
这项基于医院的横断面研究纳入了2019年3月25日至2021年3月31日期间就诊的患者。所有出现DR的患者均作为病例纳入。数据通过电子病历系统收集。
共有88,012名被诊断患有视网膜疾病的患者被纳入该网络并进行分析。研究期间有21,271名(24%)DR患者,其中大多数是来自城市地区(45%)的男性(71%)。在封锁期间(第一至四阶段),增殖性DR患者(56%)、威胁视力的DR患者(79%)、需要进行玻璃体视网膜手术的患者(31%)和玻璃体内注射的患者(19%)的数量都有所增加。在封锁前(20%)、封锁期间(32%)和封锁后(26%),失明患者的数量显著增加。初诊患者和复诊患者中威胁视力的DR和失明模式相似。
由于COVID-19大流行,DR患者在医院的就诊情况正在发生变化。解封期间(第一至十阶段)患者就诊量恢复到COVID-19前水平的三分之二。在封锁期间(第一至四阶段),威胁视力的DR患者数量增加,并且对玻璃体视网膜手术和玻璃体内注射的需求也增加。